COVID-19 Evidence Network to support Decision-making (COVID-END)

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:239 publications

Grant number: Unknown

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    2020
  • Known Financial Commitments (USD)

    $750,000
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    N/A

  • Research Location

    Canada
  • Lead Research Institution

    McMaster University
  • Research Priority Alignment

    N/A
  • Research Category

    Policies for public health, disease control & community resilience

  • Research Subcategory

    Policy research and interventions

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The science about how to prevent and manage COVID-19 and its spill-over effects on society is changing rapidly. Summaries of the best available science (which we call evidence syntheses) are the best place to turn when making decisions about public-health measures (e.g., wearing masks), clinical management (e.g., prescribing drugs), health-system arrangements (e.g., making the most of virtual doctor visits), and economic and social responses (e.g., adjusting schools and workplaces). COVID-END will bring together: 1) 25+ Canadian evidence-synthesis teams; 2) leaders of key Canadian initiatives that support the use of science by citizens, service providers and policymakers; 3) diverse citizen partners from across Canada; 4) Canadian professional bodies; and 5) policymakers and leaders from Canadian governments and health authorities. COVID-END will: 1)prepare and update evidence syntheses at the request of Canadian decision-makers in timelines ranging from 4 hours to 10 days; 2)maintain an inventory of the best evidence syntheses for COVID-19 decisions to ensure that Canadian decision-makers have available at all times the most updated summarized science; 3)work with Canadian decision-makers to ensure that their most urgent questions are prioritized and responded to by the most appropriate team in a timely way and that these decision-makers have the capacity to find and use the available science in their decision-making; 4)keep alert to emerging issues where evidence syntheses may be needed in the future; and 5)work with Canadian and global partners to reduce duplication and enhance coordination in the evidence response to COVID-19. COVID-END will undertake (or co-create) its work in close partnership with citizens and with the decision-makers who pose questions and whose existing processes we need to intersect with. COVID-END will disseminate and support the use of its work both directly and through many existing initiatives.

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

Development and Validation of the Intimate Partner Violence Workplace Disruptions Assessment (IPV-WDA).

Elucidating directed neural dynamics of scene construction across memory and imagination

Implementing a Novel Resident-Led Peer Support Program for Emergency Medicine Resident Physicians.

Cross-Activity Analysis of CRISPR/Cas9 Editing in Gene Families of <i>Solanum lycopersicum</i> Detected by Long-Read Sequencing.

Creating health systems citizens: enhanced professional identity formation through a para-curricular distinction track in health systems transformation and leadership.

A Comparison of Clinical Diagnostic Classification Criteria Used in Longitudinal Cohort Studies of the Alzheimer's Disease Continuum: A Systematic Review.

Identification and Characterization of a Rare Exon 22 Duplication in <i>CFTR</i> in Two Families.

Structural Rearrangement in Cyclic Cu(II) Pyridyltriazole Complexes: Oxidation of Dabco to Oxalate and CO<sub>2</sub> Conversion to Carbonate.

Administration of FOLFIRINOX for Advanced Pancreatic Cancer: Physician Practice Patterns During Early Use.